🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢 Live from #TLM2024 Maja Thiele sharing the long journey and team effort behind a major publication ➡️ The key is having a clear focus and perseverance ➡️ And being open to making adjustments throughout the process pubmed.ncbi.nlm.nih.gov/38218202/ AASLD Aleksander Krag

📢 Live from #TLM2024 W Ray Kim sharing the story behind the development of the SAFE score ➡️ The key to a score's success is that it addresses a real problem for pts, performs effectively, and is implemented and tested in practice. pubmed.ncbi.nlm.nih.gov/35477908/ AASLD

📢 Live from #TLM2024 A Villamil presenting the results of seladelpar vs placebo in PBC (RESPONSE trial) ➡️ Safety OK, even in pts with cirrhosis. ➡️ Seladelpar improves biochemistry (cholestasis markers). Hopefully, we’ll see hard endpoints in this field AASLD

📢 Live from #TLM2024 A meta-analysis suggests that fibrates may be a better option than OCA for patients with PBC who do not respond to UDCA. AASLD Guilherme Grossi, MD, MSc, PhD Eliabe S. Abreu, M.D. ALEH

📢 Live from #TLM2024 A cohort study by Â. Mattos shows that even lower stages of AKI in cirrhosis are associated with high mortality. AASLD ALEH

📢 Live from #TLM2024 This study by M. Pessoa & A. Trazzi, suggests that after HCV cure, antiHBc+ (HBsAg -) patients remain at higher risk for HCC than those anti-HBc - AASLD

Our Vinay Jahagirdar presenting “Initiation of naltrexone is associated with lower rates of AKI, SBP, and mortality in patients with decompensated alcohol-associated cirrhosis and ascites” at #TLM24 AASLD VCU Stravitz-Sanyal Institute for Liver Disease #LiverTwitter

Excellent presentation on behalf of CLEAREDConsortium by #RamazanIdilman from Ankara Üniversitesi #TLM2024 AASLD 🔑wide variations in 90d mortality across regions acc to country income 🔑 need to address these #disparities VCU Stravitz-Sanyal Institute for Liver Disease VCU Research VA Research

A terrific study from a terrific investigator Instead of giving 40mg of pred for 28 days because that’s how it has always been done, Anand V Kulkarni gave 40-30-20-10 Bam! Fewer infections Now let’s experiment with duration 7 vs 28 days Cc: Tony Breu

📢 Live from #TLM2024 Guadalupe GarciaTsao sharing firsthand insights on clinical trials for portal hypertension 🙌🏻 The 20-year old timolol study could have yielded similar results to PREDESCI if it had had a different design. AASLD

📢Live from #TLM2024 Elsa Solà presents results of the Global AKI Study led by Salvatore Piano Patients with AKI and ACLF showed : ➡️greater lack of resolution of AKI ➡️higher rates of HRS and ATN ➡️higher mortality (compared to those with AKI without ACLF) AASLD

📢 Live from #TLM2024 Important study by P. Huerta & Luis Antonio Díaz, MD ➡️ACLF III is a determinant of death in patients with alcohol-related hepatitis. ➡️Early referral of these pts for LT is crucial AASLD ALEH

📢 Live from #TLM2024 Hepatitis debrief by Dr. Tatyana Kushner ➡️ HBV patients with undetectable DNA have better outcomes than those with low viremia ➡️ PEG plus TDF or plus developing drugs (imdusiran) = high and durable response AASLD

📢 Live from #TLM2024 HCC debrief by Neehar Parikh ➡️ Liver stiffness may help refine HCC screening in MASLD pts ➡️ Are lower AFP levels better than the usual cutoffs for screening cured HCV, ALD, and MASLD patients? AASLD

#TLM2024 ALD & MetALD debrief by Juan Pablo (JP) Arab, MD  ➡️ Steroid tapering trial in alcohol-hepatitis ⬇️ infections vs standard approach ➡️ Many ALD pts are MetALD ➡️ In ALD, men and private insurance favors LT ➡️ Larsucosterol trial for alcohol-hepatitis AASLD ALEH

📢 Live from #TLM2024 MASLD debrief by Alina Allen Clinical trials, clinical trials, clinical trials ➡️ Efruxifermin ➡️ Efimosfermin ➡️ Semaglutide ➡️ VK2809 ➡️ ALG-055009 ➡️ Ervogastat AASLD

📢 Live from #TLM2024 Beautiful words from Maru Rinella MD about S. Harrison ❤️ AASLD

📢 Live from #TLM2024 The highly awaited semaglutide results in MASLD by P. Newsome. Impressive results from the first 800 patients who completed follow-up in the phase 3 study ESSENCE 👇🏻 AASLD

#TLM2024 has ended 🥺 Great learning & networking. Thanks @AASLD 🙏🏻 Highlights: ➡️ Symptom management & patient-centered care ➡️ Method-focused sessions: study design, clinical trials, project management . 📲 Cool app with recorded sessions 🤓 Waiting for #TLM2025

No se pierdan el Webinar ALEH + Asociación Española para el Estudio del Hígado el 📅 Jueves 15 mayo 2025. Tenemos 2 grandes speakers Sebastian Marciano y Juan Turnes que entregarán estrategias para escribir abstracts (incluyendo IA 🤖). Inscripciones ✅: eventual-latam.us12.list-manage.com/track/click?u=… AASLD EASL Education #LiverTwitter